What is Methode Ele's earnings per share (EPS)?

Methode Ele (MEI) reported diluted earnings per share of -$1.01 for fiscal year 2026. This represents a 42.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Methode Ele (MEI) Financials

MEI

Trailing 12 months to August 1, 2026

Revenue $1.0B -2.8% YoY

Net Income -$35.7M +43.0% YoY

EPS (Diluted) -$1.04 +32.9% YoY

Free Cash Flow -$13.3M -341.8% YoY

Market Cap $498.7M as of Sep 9, 2026

Price / Sales 0.5x on $1.0B revenue, trailing 12 months to August 1, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to August 1, 2026

Price / Book 0.8x on $663.1M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Aug 1, 2026 Reported Sep 2, 2026 Currency USD FYE May

Newest figures come from the 10-Q for Q1 FY2027, filed Sep 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MEI SEC filings page.

Methode Ele (MEI) reported $1.0B in revenue over the twelve months to Aug 1, 2026, down 2.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MEI FY2026 2026-08-30

Methode's earnings mechanic is a partial operating recovery: gross margin rebounds while below-operating charges keep net income negative.

Gross margin's FY2024 trough of 16.0% recovered to 19.8% by FY2026 despite shrinking sales, pointing to mix or cost improvement rather than volume-led expansion. Operating margin improved from -10.1% to 0.9%, meaning the core operation approached breakeven even as interest and other below-operating items prevented a net-profit recovery.

FY2026's net loss of -$35.7M coexisted with operating cash flow of $38M; that divergence indicates noncash charges and working-capital timing materially shaped reported earnings. After $22.4M of capital spending, free cash flow was $15.6M, so cash conversion improved without becoming substantial relative to the business.

Balance-sheet flexibility has narrowed: debt-to-equity rose from 0.2x in FY2022 to 0.5x in FY2026 as equity declined, placing the operating recovery on a less conservative capital base. The current ratio also fell from 3.3x to 2.4x, leaving current assets above current liabilities but with less excess liquidity.

Financial Health Signals

Financial Health Score 30/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Methode Ele's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Methode Ele has an operating margin of 0.9%, meaning the company retains $1 of operating profit per $100 of revenue. This below-average margin results in a low score of 21/100, suggesting thin profitability after operating expenses. This is up from -2.3% the prior year.

Growth

Methode Ele's revenue declined 2.8% year-over-year, from $1.0B to $1.0B. This contraction results in a growth score of 18/100.

Leverage

Methode Ele has elevated debt relative to equity (D/E of 0.48), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 24/100, reflecting increased financial risk.

Liquidity

With a current ratio of 2.37, Methode Ele holds $2.37 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 68/100.

Cash Flow

Methode Ele's free cash flow margin of 1.5% results in a low score of 26/100. Capital expenditures of $22.4M absorb a large share of operating cash flow.

Returns

Methode Ele posts a -5.3% return on equity (ROE), meaning it loses $5 for every $100 of shareholders' equity. This results in a returns score of 21/100. This is up from -9.0% the prior year.

Altman Z-Score Grey Zone

2.11

Methode Ele scores 2.11, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

4/9

Methode Ele passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Mixed

N/A

Methode Ele reported a net loss of $35.7M while generating $38.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

0.38x

Methode Ele earns $0.38 in operating income for every $1 of interest expense ($8.8M vs $23.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$265.4M

YoY+10.4%

QoQ-2.9%

5Y CAGR-1.6%

10Y CAGR+3.3%

Methode Ele generated $265.4M in revenue in Q1 2027. This represents an increase of 10.4% from the same quarter a year earlier. Against the prior quarter it is down 2.9%.

EBITDA

$10.2M

YoY-36.3%

QoQ-67.1%

Methode Ele's EBITDA was $10.2M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 36.3% from the same quarter a year earlier. Against the prior quarter it is down 67.1%.

Net Income

-$11.4M

YoY-10.7%

QoQ-860.0%

Methode Ele reported -$11.4M in net income in Q1 2027. This represents a decrease of 10.7% from the same quarter a year earlier. Against the prior quarter it is down 860.0%.

EPS (Diluted)

-$0.32

YoY-10.3%

Methode Ele earned -$0.32 per diluted share (EPS) in Q1 2027. This represents a decrease of 10.3% from the same quarter a year earlier.

Cash & Balance Sheet

Free Cash Flow

-$10.9M

YoY-160.6%

QoQ-1111.1%

Methode Ele recorded an outflow of $10.9M in free cash flow in Q1 2027, representing a cash shortfall after capex. This represents a decrease of 160.6% from the same quarter a year earlier. Against the prior quarter it is down 1111.1%.

Cash & Debt

$116.2M

YoY-4.0%

QoQ-16.8%

5Y CAGR-11.0%

10Y CAGR-7.3%

Methode Ele held $116.2M in cash against $310.3M in long-term debt as of Q1 2027.

Dividends Per Share

$0.05

YoY-28.6%

5Y CAGR-18.6%

10Y CAGR-5.7%

Methode Ele paid $0.05 per share in dividends in Q1 2027. This represents a decrease of 28.6% from the same quarter a year earlier.

Shares Outstanding

36M

YoY+1.2%

5Y CAGR-1.4%

10Y CAGR-0.4%

Methode Ele had 36M shares outstanding in Q1 2027. This represents an increase of 1.2% from the same quarter a year earlier.

Margins & Returns

Gross Margin

18.0%

YoY-0.1pp

QoQ-6.9pp

5Y CAGR-6.9pp

10Y CAGR-10.2pp

Methode Ele's gross margin was 18.0% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.9 percentage points.

Operating Margin

-1.5%

YoY-1.9pp

QoQ-7.3pp

Methode Ele's operating margin was -1.5% in Q1 2027, reflecting core business profitability. This is down 1.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.3 percentage points.

Net Margin

-4.3%

YoY0.0pp

QoQ-4.8pp

5Y CAGR-14.4pp

10Y CAGR-15.3pp

Methode Ele's net profit margin was -4.3% in Q1 2027, showing the share of revenue converted to profit. That is unchanged from the same quarter a year earlier. Against the prior quarter it is down 4.8 percentage points.

Return on Equity

-1.7%

YoY-0.2pp

QoQ-1.9pp

5Y CAGR-4.8pp

10Y CAGR-6.1pp

Methode Ele's ROE was -1.7% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is down 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.9 percentage points.

Capital Allocation

Capital Expenditures

$3.1M

YoY-56.3%

QoQ-46.6%

5Y CAGR-27.9%

Methode Ele invested $3.1M in capex in Q1 2027, funding long-term assets and infrastructure. This represents a decrease of 56.3% from the same quarter a year earlier. Against the prior quarter it is down 46.6%.

R&D Spending

Not reported for Q1 2027.

Share Buybacks

Not reported for Q1 2027.

MEI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MEI quarterly income statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$1.0B	$1.0B-2.8%	$1.0B-6.0%	$1.1B-5.5%	$1.2B+1.4%	$1.2B+6.9%	$1.1B+6.3%	$1.0B+2.4%	$1.0B+10.1%	$908.3M+11.2%	$816.5M+0.9%	$809.1M-8.2%	$881.1M+14.0%	$772.8M+48.7%	$519.8M+11.8%	$465.1M
Cost of Revenue	$817.0M	$817.0M-7.7%	$884.7M-5.5%	$935.7M+2.2%	$915.5M+1.9%	$898.7M+10.4%	$813.9M+9.8%	$741.0M+0.9%	$734.5M+9.8%	$668.7M+11.8%	$598.2M+0.3%	$596.2M-10.0%	$662.3M+7.5%	$616.1M+43.9%	$428.2M+12.1%	$382.0M
Gross Profit	$202.2M	$202.2M+23.7%	$163.4M-8.6%	$178.8M-32.3%	$264.1M-0.3%	$264.9M-3.4%	$274.1M-3.1%	$282.9M+6.4%	$265.8M+10.9%	$239.6M+9.8%	$218.3M+2.5%	$212.9M-2.7%	$218.8M+39.6%	$156.7M+71.1%	$91.6M+10.2%	$83.1M
R&D Expenses	N/A	$37.5M-10.3%	$41.8M-14.9%	$49.1M+40.3%	$35.0M-2.0%	$35.7M0.0%	$35.7M+2.3%	$34.9M-15.3%	$41.2M+8.7%	$37.9M+36.3%	$27.8M0.0%	$27.8M+13.5%	$24.5M-4.7%	$25.7M+8.4%	$23.7M+16.2%	$20.4M
SG&A Expenses	$170.3M	$170.3M+3.9%	$163.9M+1.9%	$160.9M+3.9%	$154.9M+15.5%	$134.1M+5.7%	$126.9M+8.6%	$116.8M-18.3%	$142.9M+23.5%	$115.7M+10.0%	$105.2M+4.4%	$100.8M+7.2%	$94.0M+18.1%	$79.6M+20.1%	$66.3M-5.2%	$69.9M
Operating Income	$8.8M	$8.8M+136.8%	-$23.9M+78.7%	-$112.0M-223.9%	$90.4M-19.1%	$111.7M-12.7%	$127.9M-13.1%	$147.1M+37.7%	$106.8M-9.7%	$118.3M+6.8%	$110.8M+1.0%	$109.7M-2.2%	$112.2M+52.4%	$73.6M+87.8%	$39.2M+243.9%	$11.4M
EBITDA	N/A	$67.6M+95.4%	$34.6M+164.0%	-$54.1M-138.7%	$139.9M-14.9%	$164.3M-8.4%	$179.4M-8.2%	$195.4M+30.2%	$150.1M+2.5%	$146.4M+8.4%	$135.1M+1.1%	$133.6M-1.5%	$135.6M+36.7%	$99.2M+71.0%	$58.0M+110.9%	$27.5M
Interest Expense	N/A	-$23.3M-5.9%	-$22.0M-31.7%	-$16.7M-518.5%	-$2.7M+22.9%	-$3.5M+32.7%	-$5.2M+48.5%	-$10.1M-21.7%	-$8.3M-822.2%	-$900K-325.0%	$400K	N/A	N/A	N/A	N/A	N/A
Income Tax	$25.0M	$25.0M+100.0%	$12.5M+360.4%	-$4.8M-136.9%	$13.0M-20.2%	$16.3M+29.4%	$12.6M-50.2%	$25.3M+110.8%	$12.0M-82.0%	$66.6M+189.6%	$23.0M-12.5%	$26.3M+32.8%	$19.8M+197.5%	-$20.3M-712.0%	-$2.5M-178.1%	$3.2M
Net Income	-$35.7M	-$35.7M+43.0%	-$62.6M+49.2%	-$123.3M-259.9%	$77.1M-24.6%	$102.2M-16.4%	$122.3M-0.9%	$123.4M+34.7%	$91.6M+60.1%	$57.2M-38.4%	$92.9M+9.8%	$84.6M-16.3%	$101.1M+5.2%	$96.1M+136.1%	$40.7M+384.5%	$8.4M
EPS (Basic)	N/A	-$1.01+42.9%	-$1.77+49.1%	-$3.48-262.6%	$2.14-21.9%	$2.74-14.9%	$3.22-1.8%	$3.28+33.9%	$2.45+59.1%	$1.54-38.2%	$2.49+12.7%	$2.21-15.3%	$2.61+3.2%	$2.53+132.1%	$1.09+395.5%	$0.22
EPS (Diluted)	-$1.04	-$1.01+42.9%	-$1.77+49.1%	-$3.48-265.7%	$2.10-22.2%	$2.70-15.4%	$3.19-2.1%	$3.26+34.2%	$2.43+59.9%	$1.52-38.7%	$2.48+12.7%	$2.20-14.4%	$2.57+2.4%	$2.51+132.4%	$1.08	$0.22
Diluted Shares (Avg)	N/A	36M+0.5%	35M-0.4%	35M-3.5%	37M-2.8%	38M-1.3%	38M+1.2%	38M+0.5%	38M+0.3%	38M+0.1%	37M-2.6%	38M-2.0%	39M+2.7%	38M+0.9%	38M	38M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Revenue	$265.4M+10.4%	$273.2M-0.7%	$233.7M-2.6%	$246.9M-15.6%	$240.5M-7.0%	$275.1M-0.8%	$239.9M-7.6%	$292.6M+1.6%
Cost of Revenue	$217.7M+10.5%	$205.2M-19.3%	$194.9M-1.9%	$199.2M-15.1%	$197.0M-7.9%	$254.4M+5.2%	$198.6M-10.7%	$234.7M-0.4%
Gross Profit	$47.7M+9.7%	$68.0M+228.5%	$38.8M-6.1%	$47.7M-17.6%	$43.5M-2.5%	$20.7M-41.7%	$41.3M+11.6%	$57.9M+10.7%
SG&A Expenses	$45.9M+25.4%	$46.3M-1.5%	$39.1M+3.7%	$39.0M-8.5%	$36.6M-20.8%	$47.0M+13.0%	$37.7M+11.2%	$42.6M+4.2%
Operating Income	-$3.9M-454.5%	$15.9M+149.4%	-$6.1M-177.3%	$2.9M-69.1%	$1.1M+114.7%	-$32.2M+47.6%	-$2.2M+26.7%	$9.4M+118.3%
EBITDA	$10.2M-36.3%	$31.0M+282.4%	$8.5M-28.6%	$17.9M-24.5%	$16.0M+142.4%	-$17.0M+63.8%	$11.9M0.0%	$23.7M+164.2%
Interest Expense	N/A	N/A	-$5.4M+1.8%	-$5.7M+8.1%	-$5.9M-22.9%	-$4.4M+2.2%	-$5.5M-10.0%	-$6.2M-40.9%
Income Tax	$4.1M-2.4%	$12.4M+1227.3%	$2.8M-54.8%	$5.7M+78.1%	$4.2M-19.2%	-$1.1M+81.0%	$6.2M+463.6%	$3.2M+1700.0%
Net Income	-$11.4M-10.7%	$1.5M+104.1%	-$15.9M-10.4%	-$9.9M-518.8%	-$10.3M+43.7%	-$36.3M+36.6%	-$14.4M-24.1%	-$1.6M+97.1%
EPS (Basic)	-$0.32-10.3%	$0.01+101.3%	-$0.45-9.8%	-$0.28-460.0%	-$0.29+44.2%	-$0.80+50.6%	-$0.41-24.2%	-$0.05+96.8%
EPS (Diluted)	-$0.32-10.3%	$0.01	-$0.45-9.8%	-$0.28-460.0%	-$0.29+44.2%	-$0.80+50.6%	-$0.41-24.2%	-$0.05+96.8%
Diluted Shares (Avg)	36M+0.9%	N/A	36M+1.2%	35M-0.1%	35M-0.1%	N/A	35M-0.4%	35M-0.5%

Not reported in any period shown, so not listed: R&D Expenses.

MEI Balance Sheet

MEI quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$1.3B0.0%	$1.3B-7.0%	$1.4B-11.1%	$1.6B+13.7%	$1.4B-5.3%	$1.5B+7.0%	$1.4B+11.3%	$1.2B+34.5%	$915.9M+30.1%	$704.0M+7.3%	$655.9M+8.3%	$605.8M+5.3%	$575.5M+32.3%	$434.9M+7.8%	$403.6M
Current Assets	$600.0M+7.2%	$559.9M-12.2%	$637.7M-4.0%	$664.4M+5.6%	$629.0M-6.7%	$674.0M+19.2%	$565.6M+24.7%	$453.5M-17.5%	$550.0M+3.7%	$530.3M+6.9%	$496.2M+13.2%	$438.3M+14.8%	$381.7M+47.6%	$258.6M+7.6%	$240.4M
Cash & Equivalents	$139.6M+34.7%	$103.6M-35.9%	$161.5M+2.9%	$157.0M-8.7%	$172.0M-26.2%	$233.2M+7.3%	$217.3M+161.2%	$83.2M-66.2%	$246.1M-16.3%	$294.0M+29.1%	$227.8M+35.5%	$168.1M+44.4%	$116.4M+76.9%	$65.8M-24.2%	$86.8M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$178.7M-7.9%	$194.1M+4.2%	$186.2M+16.6%	$159.7M+0.8%	$158.5M+27.6%	$124.2M-5.2%	$131.0M+12.3%	$116.7M+38.8%	$84.1M+45.3%	$57.9M-12.5%	$66.2M-6.6%	$70.9M-1.0%	$71.6M+19.5%	$59.9M+37.5%	$43.6M
Accounts Receivable	$257.3M+6.8%	$241.0M-8.2%	$262.6M-16.4%	$314.3M+15.0%	$273.3M-3.3%	$282.5M+49.9%	$188.5M-14.0%	$219.3M+8.2%	$202.6M+22.6%	$165.3M-5.8%	$175.5M+3.0%	$170.4M-1.5%	$173.0M+44.4%	$119.8M+21.8%	$98.4M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$174.9M+1.3%	$172.7M+1.6%	$169.9M-43.7%	$301.9M+29.6%	$233.0M-1.1%	$235.6M+1.7%	$231.6M-0.7%	$233.3M+294.1%	$59.2M+3600.0%	$1.6M-5.9%	$1.7M-86.9%	$13.0M0.0%	$13.0M-24.4%	$17.2M+4.9%	$16.4M
Total Liabilities	$628.6M+2.6%	$612.5M-3.9%	$637.5M+1.8%	$626.2M+31.7%	$475.3M-13.4%	$549.0M-6.5%	$587.2M+8.3%	$542.0M+89.6%	$285.9M+75.5%	$162.9M-12.3%	$185.8M+26.4%	$147.0M-19.9%	$183.6M+26.2%	$145.5M-2.1%	$148.6M
Current Liabilities	$253.5M+8.7%	$233.2M+0.8%	$231.4M+1.5%	$228.0M+20.9%	$188.6M-15.3%	$222.7M+54.9%	$143.8M-20.5%	$180.9M+15.2%	$157.0M+26.2%	$124.4M+5.5%	$117.9M-9.7%	$130.6M+9.7%	$119.1M+31.7%	$90.4M-1.6%	$91.9M
Non-Current Liabilities	$375.1M-1.1%	$379.3M-6.6%	$406.1M+2.0%	$398.2M+38.9%	$286.7M-12.1%	$326.3M-26.4%	$443.4M+22.8%	$361.1M+180.1%	$128.9M+234.8%	$38.5M-43.3%	$67.9M+314.0%	$16.4M-74.6%	$64.5M+17.1%	$55.1M-2.8%	$56.7M
Long-Term Debt	$324.8M+2.3%	$317.4M-4.0%	$330.7M+8.9%	$303.6M+53.7%	$197.5M-12.3%	$225.2M-33.1%	$336.8M+21.6%	$276.9M+418.5%	$53.4M+97.8%	$27.0M-52.6%	$57.0M+1040.0%	$5.0M-89.6%	$48.0M+10.3%	$43.5M-9.4%	$48.0M
Total Equity	$677.5M-2.3%	$693.3M-9.5%	$766.0M-18.7%	$941.8M+3.1%	$913.8M-0.5%	$918.0M+17.2%	$783.4M+13.6%	$689.7M+9.5%	$630.0M+16.4%	$541.1M+15.1%	$470.1M+2.5%	$458.8M+17.1%	$391.9M+35.4%	$289.4M+13.5%	$255.0M
Retained Earnings	$479.3M-8.6%	$524.2M-14.4%	$612.3M-20.8%	$772.7M+1.2%	$763.9M+2.4%	$746.0M+14.4%	$651.9M+19.6%	$545.2M+15.5%	$472.0M+10.5%	$427.0M+19.1%	$358.6M+0.6%	$356.5M+32.4%	$269.2M+46.0%	$184.4M+19.7%	$154.0M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$1.3B-2.1%	$1.3B0.0%	$1.3B+0.1%	$1.3B-6.4%	$1.3B-6.3%	$1.3B-7.0%	$1.3B-12.5%	$1.4B-7.4%
Current Assets	$584.4M+6.4%	$600.0M+7.2%	$585.3M+2.3%	$555.3M-9.4%	$549.2M-10.2%	$559.9M-12.2%	$572.2M-9.1%	$612.9M-3.7%
Cash & Equivalents	$116.2M-4.0%	$139.6M+34.7%	$133.7M+28.8%	$118.5M+22.2%	$121.1M+8.8%	$103.6M-35.9%	$103.8M-15.5%	$97.0M-20.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$184.6M-3.3%	$178.7M-7.9%	$209.8M-4.1%	$190.2M-16.7%	$190.9M-13.2%	$194.1M+4.2%	$218.8M+7.3%	$228.2M+24.1%
Accounts Receivable	$256.4M+18.9%	$257.3M+6.8%	$215.6M-2.0%	$229.6M-10.3%	$215.6M-13.3%	$241.0M-8.2%	$220.0M-17.1%	$255.9M-12.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$173.5M-0.2%	$174.9M+1.3%	$175.5M+4.8%	$173.4M+1.8%	$173.9M+1.9%	$172.7M+1.6%	$167.4M-24.0%	$170.4M-22.8%
Total Liabilities	$600.6M-0.4%	$628.6M+2.6%	$631.3M+5.2%	$608.1M-4.5%	$603.2M-4.8%	$612.5M-3.9%	$600.3M-8.6%	$636.8M-0.5%
Current Liabilities	$242.3M+10.3%	$253.5M+8.7%	$242.8M+20.6%	$217.6M-2.2%	$219.6M-15.8%	$233.2M+0.8%	$201.4M-12.4%	$222.6M+2.0%
Non-Current Liabilities	$358.3M-6.6%	$375.1M-1.1%	$388.5M-2.6%	$390.5M-5.7%	$383.6M+2.9%	$379.3M-6.6%	$398.9M-6.5%	$414.2M-1.8%
Long-Term Debt	$310.3M-4.0%	$324.8M+2.3%	$340.7M+4.0%	$332.3M-2.4%	$323.2M+9.3%	$317.4M-4.0%	$327.7M-1.0%	$340.4M+3.5%
Total Equity	$663.1M-3.6%	$677.5M-2.3%	$675.0M-4.2%	$679.3M-8.0%	$688.1M-7.6%	$693.3M-9.5%	$704.3M-15.7%	$738.3M-12.6%
Retained Earnings	$465.4M-8.9%	$479.3M-8.6%	$481.0M-13.8%	$498.9M-14.1%	$511.0M-13.0%	$524.2M-14.4%	$558.3M-17.6%	$580.6M-16.7%

MEI Cash Flow Statement

MEI quarterly cash flow statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$5.1M	$38.0M+43.9%	$26.4M-44.4%	$47.5M-64.2%	$132.8M+34.4%	$98.8M-45.1%	$179.8M+27.9%	$140.6M+37.8%	$102.0M-13.4%	$117.8M-18.9%	$145.2M+31.2%	$110.7M-9.9%	$122.9M+69.8%	$72.4M+118.1%	$33.2M+33.9%	$24.8M
Depreciation & Amortization	N/A	$58.8M+0.5%	$58.5M+1.0%	$57.9M+17.0%	$49.5M-5.9%	$52.6M+2.1%	$51.5M+6.6%	$48.3M+11.5%	$43.3M+54.1%	$28.1M+15.6%	$24.3M+1.7%	$23.9M+2.1%	$23.4M-8.6%	$25.6M+36.2%	$18.8M+16.8%	$16.1M
Stock-Based Compensation	N/A	$8.5M+14.9%	$7.4M+105.6%	$3.6M-68.7%	$11.5M-2.5%	$11.8M+73.5%	$6.8M+2166.7%	$300K-97.9%	$14.0M+250.0%	$4.0M-67.7%	$12.4M+67.6%	$7.4M+72.1%	$4.3M+30.3%	$3.3M0.0%	$3.3M-17.5%	$4.0M
Capital Expenditures	$18.4M	$22.4M-46.2%	$41.6M-17.1%	$50.2M+19.5%	$42.0M+10.5%	$38.0M+52.6%	$24.9M-44.8%	$45.1M-9.4%	$49.8M+4.4%	$47.7M+112.9%	$22.4M-3.4%	$23.2M+3.1%	$22.5M-22.4%	$29.0M-24.9%	$38.6M+50.2%	$25.7M
Free Cash Flow	-$13.3M	$15.6M+202.6%	-$15.2M-463.0%	-$2.7M-103.0%	$90.8M+49.3%	$60.8M-60.7%	$154.9M+62.2%	$95.5M+83.0%	$52.2M-25.5%	$70.1M-42.9%	$122.8M+40.3%	$87.5M-12.8%	$100.4M+131.3%	$43.4M+903.7%	-$5.4M-500.0%	-$900K
Investing Cash Flow	$4.0M	$1.3M+104.0%	-$32.9M-88.0%	-$17.5M+88.6%	-$153.1M-309.4%	-$37.4M-50.8%	-$24.8M+44.3%	-$44.5M+90.5%	-$470.8M-163.0%	-$179.0M-724.9%	-$21.7M-0.5%	-$21.6M-91.2%	-$11.3M+50.7%	-$22.9M+42.8%	-$40.0M-24.6%	-$32.1M
Financing Cash Flow	-$22.0M	-$14.2M+75.9%	-$58.9M-211.6%	-$18.9M-690.6%	$3.2M+102.8%	-$114.6M+19.8%	-$142.9M-442.7%	$41.7M-80.8%	$217.4M+1811.8%	-$12.7M+73.0%	-$47.0M-63.8%	-$28.7M+40.8%	-$48.5M-3364.3%	-$1.4M+90.1%	-$14.2M-137.5%	$37.9M
Dividends Paid	$7.3M	$8.3M-59.3%	$20.4M+2.5%	$19.9M+0.5%	$19.8M-2.9%	$20.4M+17.2%	$17.4M+6.7%	$16.3M0.0%	$16.3M+10.9%	$14.7M+7.3%	$13.7M+1.5%	$13.5M-2.2%	$13.8M+22.1%	$11.3M+9.7%	$10.3M-1.0%	$10.4M
Share Buybacks	N/A	$0-100.0%	$1.6M-88.3%	$13.7M-71.5%	$48.1M-25.4%	$64.5M+862.7%	$6.7M	N/A	$0	$0-100.0%	$9.8M-84.3%	$62.3M	$0	$0	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	-$7.8M-131.1%	$4.9M-86.2%	$15.4M-45.2%	-$7.4M+84.6%	$25.1M+130.3%	$35.4M+42.2%	$28.1M-2.4%	-$48.0M-7900.0%
Depreciation & Amortization	$14.1M-5.4%	$14.3M-10.6%	$14.6M+3.5%	$15.0M+4.9%	$14.9M+5.7%	$16.0M+9.6%	$14.1M-5.4%	$14.3M-0.7%
Stock-Based Compensation	$2.1M+75.0%	N/A	N/A	N/A	$1.2M-45.5%	N/A	N/A	N/A
Capital Expenditures	$3.1M-56.3%	$5.8M-36.3%	$5.3M-37.6%	$4.2M-59.6%	$7.1M-47.8%	$9.1M0.0%	$8.5M-48.8%	$10.4M-2.8%
Free Cash Flow	-$10.9M-160.6%	-$900K-103.4%	$10.1M-48.5%	-$11.6M+80.1%	$18.0M+766.7%	$26.3M+66.5%	$19.6M+60.7%	-$58.4M-416.8%
Investing Cash Flow	-$3.1M+46.6%	$14.9M+340.3%	-$4.1M+28.1%	-$3.7M+50.0%	-$5.8M+57.4%	-$6.2M-128.8%	-$5.7M+65.9%	-$7.4M+12.9%
Financing Cash Flow	-$12.3M-173.3%	-$15.2M+64.1%	-$2.1M+75.3%	$7.6M-81.0%	-$4.5M+90.7%	-$42.3M-984.6%	-$8.5M+49.7%	$40.1M+478.3%
Dividends Paid	$1.8M-35.7%	$1.8M-64.7%	$1.8M-66.0%	$1.9M-61.2%	$2.8M-45.1%	$5.1M+4.1%	$5.3M+8.2%	$4.9M+2.1%
Share Buybacks	N/A	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0

MEI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MEI quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	19.8%+4.2pp	15.6%-0.4pp	16.0%-6.3pp	22.4%-0.4pp	22.8%-2.4pp	25.2%-2.4pp	27.6%+1.1pp	26.6%+0.2pp	26.4%-0.4pp	26.7%+0.4pp	26.3%+1.5pp	24.8%+4.5pp	20.3%+2.7pp	17.6%-0.3pp	17.9%
Operating Margin	0.9%+3.1pp	-2.3%+7.8pp	-10.1%-17.7pp	7.7%-1.9pp	9.6%-2.2pp	11.8%-2.6pp	14.4%+3.7pp	10.7%-2.3pp	13.0%-0.5pp	13.6%0.0pp	13.6%+0.8pp	12.7%+3.2pp	9.5%+2.0pp	7.5%+5.1pp	2.5%
Net Margin	-3.5%+2.5pp	-6.0%+5.1pp	-11.1%-17.6pp	6.5%-2.2pp	8.8%-2.5pp	11.2%-0.8pp	12.0%+2.9pp	9.2%+2.9pp	6.3%-5.1pp	11.4%+0.9pp	10.5%-1.0pp	11.5%-1.0pp	12.4%+4.6pp	7.8%+6.0pp	1.8%
Return on Equity	-5.3%+3.8pp	-9.0%+7.1pp	-16.1%-24.3pp	8.2%-3.0pp	11.2%-2.1pp	13.3%-2.4pp	15.8%+2.5pp	13.3%+4.2pp	9.1%-8.1pp	17.2%-0.8pp	18.0%-4.0pp	22.0%-2.5pp	24.5%+10.5pp	14.1%+10.8pp	3.3%
Return on Assets	-2.7%+2.1pp	-4.8%+4.0pp	-8.8%-13.7pp	4.9%-2.5pp	7.4%-1.0pp	8.3%-0.7pp	9.0%+1.6pp	7.4%+1.2pp	6.3%-7.0pp	13.2%+0.3pp	12.9%-3.8pp	16.7%0.0pp	16.7%+7.3pp	9.4%+7.3pp	2.1%
Current Ratio	2.370.0x	2.40-0.4x	2.76-0.2x	2.91-0.4x	3.34+0.3x	3.03-0.9x	3.93+1.4x	2.51-1.0x	3.50-0.8x	4.26+0.1x	4.21+0.9x	3.36+0.2x	3.20+0.3x	2.86+0.2x	2.62
Debt-to-Equity	0.480.0x	0.460.0x	0.43+0.1x	0.32+0.1x	0.220.0x	0.25-0.2x	0.430.0x	0.40+0.3x	0.080.0x	0.05-0.1x	0.12+0.1x	0.01-0.1x	0.120.0x	0.150.0x	0.19
Asset Turnover	0.780.0x	0.800.0x	0.790.0x	0.75-0.1x	0.84+0.1x	0.740.0x	0.75-0.1x	0.81-0.2x	0.99-0.2x	1.16-0.1x	1.23-0.2x	1.45+0.1x	1.34+0.1x	1.200.0x	1.15
FCF Margin	1.5%+3.0pp	-1.5%-1.2pp	-0.2%-7.9pp	7.7%+2.5pp	5.2%-9.0pp	14.2%+4.9pp	9.3%+4.1pp	5.2%-2.5pp	7.7%-7.3pp	15.0%+4.2pp	10.8%-0.6pp	11.4%+5.8pp	5.6%+6.7pp	-1.0%-0.8pp	-0.2%

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Gross Margin	18.0%-0.1pp	24.9%+17.4pp	16.6%-0.6pp	19.3%-0.5pp	18.1%+0.8pp	7.5%-5.3pp	17.2%+3.0pp	19.8%+1.6pp
Operating Margin	-1.5%-1.9pp	5.8%+17.5pp	-2.6%-1.7pp	1.2%-2.0pp	0.5%+3.4pp	-11.7%+10.5pp	-0.9%+0.2pp	3.2%+21.0pp
Net Margin	-4.3%0.0pp	0.5%+13.8pp	-6.8%-0.8pp	-4.0%-3.5pp	-4.3%+2.8pp	-13.2%+7.5pp	-6.0%-1.5pp	-0.5%+18.6pp
Return on Equity	-1.7%-0.2pp	0.2%+5.5pp	-2.4%-0.3pp	-1.5%-1.2pp	-1.5%+1.0pp	-5.2%+2.2pp	-2.0%-0.7pp	-0.2%+6.3pp
Return on Assets	-0.9%-0.1pp	0.1%+2.9pp	-1.2%-0.1pp	-0.8%-0.7pp	-0.8%+0.5pp	-2.8%+1.3pp	-1.1%-0.3pp	-0.1%+3.6pp
Current Ratio	2.41-0.1x	2.370.0x	2.41-0.4x	2.55-0.2x	2.50+0.2x	2.40-0.4x	2.84+0.1x	2.75-0.2x
Debt-to-Equity	0.470.0x	0.480.0x	0.500.0x	0.490.0x	0.47+0.1x	0.460.0x	0.47+0.1x	0.46+0.1x
Asset Turnover	0.210.0x	0.210.0x	0.180.0x	0.190.0x	0.190.0x	0.210.0x	0.180.0x	0.210.0x
FCF Margin	-4.1%-11.6pp	-0.3%-9.9pp	4.3%-3.8pp	-4.7%+15.3pp	7.5%+8.5pp	9.6%+3.9pp	8.2%+3.5pp	-20.0%-16.0pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Methode Ele MEI	FY2026	$1.0B	-$35.7M	-3.5%	$498.7M	30/100
Lightpath Technologies Inc LPTH	FY2025	$37.2M	-$14.9M	-40.0%	$675.0M	29/100
Kulr Technology KULR	FY2025	$16.2M	-$61.9M	N/A	$115.7M	50/100
Richardson Electrs Ltd RELL	FY2026	$228.6M	$6.4M	2.8%	$262.1M	53/100
M Tron Ind MPTI	FY2025	$54.4M	$8.4M	15.5%	$330.6M	81/100
Gauzy Ltd GAUZ	FY2024	$103.5M	-$53.2M	-51.4%	$8.7M	38/100

Where Methode Ele Ranks

Frequently Asked Questions

What is Methode Ele's annual revenue?

Methode Ele (MEI) reported $1.0B in total revenue for fiscal year 2026. This represents a -2.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Methode Ele's revenue growing?

Methode Ele (MEI) revenue declined by 2.8% year-over-year, from $1.0B to $1.0B in fiscal year 2026.

Is Methode Ele profitable?

No, Methode Ele (MEI) reported a net income of -$35.7M in fiscal year 2026, with a net profit margin of -3.5%.

What is Methode Ele's EBITDA?

Methode Ele (MEI) had EBITDA of $67.6M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Methode Ele have?

As of fiscal year 2026, Methode Ele (MEI) had $139.6M in cash and equivalents against $324.8M in long-term debt.

What is Methode Ele's gross margin?

Methode Ele (MEI) had a gross margin of 19.8% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Methode Ele's operating margin?

Methode Ele (MEI) had an operating margin of 0.9% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Methode Ele's net profit margin?

Methode Ele (MEI) had a net profit margin of -3.5% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

Does Methode Ele pay dividends?

Yes, Methode Ele (MEI) paid $0.22 per share in dividends during fiscal year 2026.

What is Methode Ele's return on equity (ROE)?

Methode Ele (MEI) has a return on equity of -5.3% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Methode Ele's free cash flow?

Methode Ele (MEI) generated $15.6M in free cash flow during fiscal year 2026. This represents a 202.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Methode Ele's operating cash flow?

Methode Ele (MEI) generated $38.0M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Methode Ele's total assets?

Methode Ele (MEI) had $1.3B in total assets as of fiscal year 2026, including both current and long-term assets.

What are Methode Ele's capital expenditures?

Methode Ele (MEI) invested $22.4M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Methode Ele spend on research and development?

Methode Ele (MEI) invested $37.5M in research and development during fiscal year 2026.

How many shares does Methode Ele have outstanding?

Methode Ele (MEI) had 35M shares outstanding as of fiscal year 2026.

What is Methode Ele's current ratio?

Methode Ele (MEI) had a current ratio of 2.37 as of fiscal year 2026, which is generally considered healthy.

What is Methode Ele's debt-to-equity ratio?

Methode Ele (MEI) had a debt-to-equity ratio of 0.48 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Methode Ele's return on assets (ROA)?

Methode Ele (MEI) had a return on assets of -2.7% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Methode Ele's P/E ratio?

Methode Ele (MEI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to August 1, 2026). The market capitalization is $498.7M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Methode Ele's price-to-sales ratio?

Methode Ele (MEI) trades at 0.5x sales, its market capitalization divided by revenue of $1.0B revenue, trailing 12 months to August 1, 2026. The market capitalization is $498.7M as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Methode Ele's Altman Z-Score?

Methode Ele (MEI) has an Altman Z-Score of 2.11, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Methode Ele's Piotroski F-Score?

Methode Ele (MEI) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Methode Ele's earnings high quality?

Methode Ele (MEI) reported a net loss of $35.7M while generating $38.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Methode Ele cover its interest payments?

Methode Ele (MEI) has an interest coverage ratio of 0.38x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Methode Ele?

Methode Ele (MEI) scores 30 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.